Literature DB >> 22535637

Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing.

Diana Vetter1, Michal Cohen-Naftaly, Augusto Villanueva, Youngmin A Lee, Peri Kocabayoglu, Rebekka Hannivoort, Goutham Narla, Josep M Llovet, Swan N Thung, Scott L Friedman.   

Abstract

UNLABELLED: KLF6-SV1 (SV1), the major splice variant of KLF6, antagonizes the KLF6 tumor suppressor by an unknown mechanism. Decreased KLF6 expression in human hepatocellular carcinoma (HCC) correlates with increased mortality, but the contribution of increased SV1 is unknown. We sought to define the impact of SV1 on human outcomes and experimental murine hepatocarcinogenesis and to elucidate its mechanism of action. In hepatitis C virus (HCV)-related HCC, an increased ratio of SV1/KLF6 within the tumor was associated with features of more advanced disease. Six months after a single injection of diethylnitrosamine (DEN), SV1 hepatocyte transgenic mice developed more histologically advanced tumors, whereas Klf6-depleted mice developed bigger tumors compared to the Klf6fl(+/+) control mice. Nine months after DEN, SV1 transgenic mice with Klf6 depletion had the greatest tumor burden. Primary mouse hepatocytes from both the SV1 transgenic animals and those with hepatocyte-specific Klf6 depletion displayed increased DNA synthesis, with an additive effect in hepatocytes harboring both SV1 overexpression and Klf6 depletion. Parallel results were obtained by viral SV1 transduction and depletion of Klf6 through adenovirus-Cre infection of primary Klf6fl(+/+) hepatocytes. Increased DNA synthesis was due to both enhanced cell proliferation and increased ploidy. Coimmunoprecipitation studies in 293T cells uncovered a direct interaction of transfected SV1 with KLF6. Accelerated KLF6 degradation in the presence of SV1 was abrogated by the proteasome inhibitor MG132.
CONCLUSION: An increased SV1/KLF6 ratio correlates with more aggressive HCC. In mice, an increased SV1/KLF6 ratio, generated either by increasing SV1, decreasing KLF6, or both, accelerates hepatic carcinogenesis. Moreover, SV1 binds directly to KLF6 and accelerates its degradation. These findings represent a novel mechanism underlying the antagonism of tumor suppressor gene function by a splice variant of the same gene.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22535637      PMCID: PMC3412196          DOI: 10.1002/hep.25810

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

1.  A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function.

Authors:  Daniela A Slavin; Nicolás P Koritschoner; Claudio C Prieto; Fernando J López-Díaz; Bruno Chatton; José Luis Bocco
Journal:  Oncogene       Date:  2004-10-28       Impact factor: 9.867

2.  KLF6, a candidate tumor suppressor gene mutated in prostate cancer.

Authors:  G Narla; K E Heath; H L Reeves; D Li; L E Giono; A C Kimmelman; M J Glucksman; J Narla; F J Eng; A M Chan; A C Ferrari; J A Martignetti; S L Friedman
Journal:  Science       Date:  2001-12-21       Impact factor: 47.728

3.  Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.

Authors:  Analisa DiFeo; Goutham Narla; Jennifer Hirshfeld; Olga Camacho-Vanegas; Jyothsna Narla; Stephen L Rose; Tamara Kalir; Shen Yao; Alice Levine; Michael J Birrer; Tomas Bonome; Scott L Friedman; Richard E Buller; John A Martignetti
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

4.  A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk.

Authors:  Goutham Narla; Analisa Difeo; Helen L Reeves; Daniel J Schaid; Jennifer Hirshfeld; Eldad Hod; Amanda Katz; William B Isaacs; Scott Hebbring; Akira Komiya; Shannon K McDonnell; Kathleen E Wiley; Steven J Jacobsen; Sarah D Isaacs; Patrick C Walsh; S Lilly Zheng; Bao-Li Chang; Danielle M Friedrichsen; Janet L Stanford; Elaine A Ostrander; Arul M Chinnaiyan; Mark A Rubin; Jianfeng Xu; Stephen N Thibodeau; Scott L Friedman; John A Martignetti
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

5.  Genetic alterations of the KLF6 gene in gastric cancer.

Authors:  Yong Gu Cho; Chang Jae Kim; Cho Hyun Park; Young Mok Yang; Su Young Kim; Suk Woo Nam; Sug Hyung Lee; Nam Jin Yoo; Jung Young Lee; Won Sang Park
Journal:  Oncogene       Date:  2005-06-30       Impact factor: 9.867

6.  Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.

Authors:  Lars P Bechmann; Amalia Gastaldelli; Diana Vetter; Gillian L Patman; Laura Pascoe; Rebekka A Hannivoort; Ursula E Lee; Isabel Fiel; Ursula Muñoz; Demetrio Ciociaro; Young-Min Lee; Emma Buzzigoli; Luca Miele; Kei Y Hui; Elisabetta Bugianesi; Alastair D Burt; Christopher P Day; Andrea Mari; Loranne Agius; Mark Walker; Scott L Friedman; Helen L Reeves
Journal:  Hepatology       Date:  2012-03-01       Impact factor: 17.425

7.  Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma.

Authors:  Sigal Kremer-Tal; Helen L Reeves; Goutham Narla; Swan N Thung; Myron Schwartz; Analisa Difeo; Amanda Katz; Jordi Bruix; Paulette Bioulac-Sage; John A Martignetti; Scott L Friedman
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

8.  Regulation of human p53 activity and cell localization by alternative splicing.

Authors:  Anirban Ghosh; Deborah Stewart; Greg Matlashewski
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

9.  Krüppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells.

Authors:  Genshi Ito; Mika Uchiyama; Masashi Kondo; Shoichi Mori; Noriyasu Usami; Osamu Maeda; Tsutomu Kawabe; Yoshinori Hasegawa; Kaoru Shimokata; Yoshitaka Sekido
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

10.  Gene expression profiling predicts clinical outcome of prostate cancer.

Authors:  Gennadi V Glinsky; Anna B Glinskii; Andrew J Stephenson; Robert M Hoffman; William L Gerald
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

View more
  22 in total

Review 1.  Splicing alterations contributing to cancer hallmarks in the liver: central role of dedifferentiation and genome instability.

Authors:  Maddalen Jimenez; María Arechederra; Matías A Ávila; Carmen Berasain
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-31

Review 2.  Krüppel-like factors in cancer.

Authors:  Marie-Pier Tetreault; Yizeng Yang; Jonathan P Katz
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 3.  SP and KLF Transcription Factors in Digestive Physiology and Diseases.

Authors:  Chang-Kyung Kim; Ping He; Agnieszka B Bialkowska; Vincent W Yang
Journal:  Gastroenterology       Date:  2017-03-30       Impact factor: 22.682

Review 4.  Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes.

Authors:  Yuan-Chi Teng; Zhao-Qing Shen; Cheng-Heng Kao; Ting-Fen Tsai
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 5.  Alterations in the expression and activity of pre-mRNA splicing factors in hepatocarcinogenesis.

Authors:  Carmen Berasain; María Elizalde; Raquel Urtasun; Josefa Castillo; Oihane García-Irigoyen; Iker Uriarte; Maria U Latasa; Jesús Prieto; Matías A Avila
Journal:  Hepat Oncol       Date:  2014-03-20

6.  Ah Receptor Pathway Intricacies; Signaling Through Diverse Protein Partners and DNA-Motifs.

Authors:  D P Jackson; A D Joshi; C J Elferink
Journal:  Toxicol Res (Camb)       Date:  2015-03-17       Impact factor: 3.524

7.  Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma.

Authors:  Fu-Yao Liu; Yue-Ling Deng; Yuan Li; Dan Zeng; Zhen-Zhen Zhou; De-An Tian; Mei Liu
Journal:  Med Oncol       Date:  2013-01-17       Impact factor: 3.064

8.  Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis.

Authors:  Lars P Bechmann; Diana Vetter; Junichi Ishida; Rebekka A Hannivoort; Ursula E Lang; Peri Kocabayoglu; M Isabel Fiel; Ursula Muñoz; Gillian L Patman; Fengxia Ge; Shoshana Yakar; Xiaosong Li; Loranne Agius; Young-Min Lee; Weijia Zhang; Kei Yiu Hui; Despina Televantou; Gary J Schwartz; Derek LeRoith; Paul D Berk; Ryozo Nagai; Toru Suzuki; Helen L Reeves; Scott L Friedman
Journal:  J Hepatol       Date:  2013-01-23       Impact factor: 25.083

9.  KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.

Authors:  Raheleh Hatami; Anieta M Sieuwerts; Sudeh Izadmehr; Zhong Yao; Rui Fang Qiao; Luena Papa; Maxime P Look; Marcel Smid; Jessica Ohlssen; Alice C Levine; Doris Germain; David Burstein; Alexander Kirschenbaum; Analisa DiFeo; John A Foekens; Goutham Narla
Journal:  Sci Transl Med       Date:  2013-01-23       Impact factor: 17.956

10.  Kruppel-like factor 6 suppresses growth and invasion of hepatocellular carcinoma cells in vitro and in vivo.

Authors:  Pei-Hao Wen; Dong-Yu Wang; Jia-Kai Zhang; Zhi-Hui Wang; Jie Pan; Xiao-Yi Shi; Han Yang; Shui-Jun Zhang; Wen-Zhi Guo
Journal:  Int J Immunopathol Pharmacol       Date:  2016-08-10       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.